SURMOUNT-2

Definition

Tirzepatide in adults with obesity AND type 2 diabetes (Garvey et al., Lancet 2023). Tirzepatide 15 mg gave −14.7% body weight at 72 weeks against −3.2% on placebo, with HbA1c reductions beyond most diabetes-specific GLP-1 trials. It supported extending Zepbound labeling toward the T2D-with-obesity population.

SURMOUNT-2 trial deep-dive →

GLP Watchdog writes these definitions from FDA labels and peer-reviewed PubMed literature. Not one of them is an AI-generated summary.

Other terms under trial

• SURMOUNT-5
• SURMOUNT-3
• SURPASS-2
• SUSTAIN-6
• REWIND
• PIONEER 6
• STEP-HFpEF
• EXSCEL
• ELIXA
• AMPLITUDE-O
• HARMONY OUTCOMES
• SCALE Diabetes
• STEP 2
• SUMMIT
• SCALE Maintenance

Where the evidence lives

• SURMOUNT-2 trial deep-dive
• The full GLP-1 glossary (149 terms, 8 categories)
• Research articles — written from primary sources
• Tools and calculators
• Compare GLP-1 telehealth providers